CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
GAITHERSBURG, Md., April 06, 2016 -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference.
Conference details are as follows:
Date: Wednesday, April 13, 2016
Time: 8:40 a.m. U.S. Eastern Time
Location: Westin Grand Central hotel, New York City
Live webcast: http://wsw.com/webcast/needham76/nvax
The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
[email protected]
[email protected]
212-845-4271
